In a phase 2b HARMONY study, efruxifermin showed significant improvement in fibrosis at week 24, sustained through week 96 in patients with metabolic dysfunction-associated steatohepatitis who had fibrosis stage 2 or 3. One-third of patients had a two-stage improvement in fibrosis with no worsening of MASH. Efruxifermin also resulted in resolution of MASH without worsening of fibrosis in a majority of patients. The treatment was generally well-tolerated, with diarrhea and nausea being the most frequent drug-related adverse events. These results suggest a potential breakthrough in antifibrotic therapy for patients with MASH and advanced fibrosis.
Source link
‘Unprecedented level of fibrosis improvement’ through 96 weeks with efruxifermin for MASH
